GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Eyenovia Inc.
Eyenovia is a biopharmaceutical company developing a technology for delivering medications to the eye using microdroplets. Its stock price is a bet that its innovative method will prove more convenient and effective than traditional eye drops.
Share prices of companies in the market segment - Pharma eyes
Eyenovia is an ophthalmology company developing microdosing technology for eye drop delivery, improving their effectiveness. We've categorized it under "Pharma: Eyes," and the chart below shows how investors view innovative approaches to treating eye diseases.
Broad Market Index - GURU.Markets
Eyenovia is an ophthalmology company that has developed microdosing technology for eye drops, improving their effectiveness and convenience. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Eyenovia compares to it.
Change in the price of a company, segment, and market as a whole per day
EYEN - Daily change in the company's share price Eyenovia Inc.
Eyenovia, Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its eye disease treatments.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Eyenovia develops innovative ophthalmic drug delivery devices, aiming to improve the treatment of eye diseases. The pharmaceutical industry, especially in niche markets, is volatile. The graph below shows average fluctuations in this sector, allowing one to assess the market acceptance of EYEN's technologies.
Daily change in the price of a broad market stock, index - GURU.Markets
Eyenovia is a biotech company specializing in the treatment of eye diseases using microdosing technology. Its stock price depends on clinical trial success and regulatory approval. These events create unique price movements.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Eyenovia Inc.
For Eyenovia, Inc., year-over-year performance is a story about its unique eye drop delivery technology. Its 12-month market capitalization is entirely dependent on FDA decisions regarding its drugs. The success of its microdosing device could be a breakthrough, offering a more precise and convenient way to treat eye diseases.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Eyenovia, Inc. is a biopharmaceutical company developing treatments for eye diseases using its unique microdosing technology. This chart shows how the market views its innovative platform, clinical trial results, and the commercial potential of its products.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Eyenovia, with its micro-eyedrop technology, is trying to change ophthalmology. Its market momentum is driven by anticipation of FDA approval and commercial success. A positive regulatory approval could trigger explosive growth, as its technology promises to be more convenient than traditional eye drops.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Eyenovia Inc.
Eyenovia is an ophthalmology company with a unique microdosing technology. Its monthly growth is entirely dependent on FDA regulatory decisions regarding its drugs and on progress in commercializing its technology through partnerships.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Eyenovia, Inc. is developing an innovative method for delivering medications to the eye using microdroplet technology, which could improve the effectiveness and convenience of treatment. The ophthalmology sector is growing thanks to an aging population. Against this backdrop, Eyenovia is striving to establish its delivery method as a new standard, addressing the inaccuracy of traditional eye drops.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Eyenovia, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of eye diseases using its unique microdosing technology. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its innovative drug delivery technology impacts its valuation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Eyenovia Inc.
Eyenovia, Inc. is a late-stage ophthalmology company developing technology for microdroplet drug delivery to the eye. Its weekly stock price is driven by news of its FDA approval process.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Eyenovia develops innovative devices for drug delivery to the eye, which could transform ophthalmology. The company's success depends on regulatory approval and the acceptance of its technology. The chart will reveal whether Eyenovia's share price performance is driven by its unique progress or by a general investor reaction to developments in the sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Eyenovia is an early-stage pharmaceutical company. Its shares are trading in anticipation of trial results. The chart clearly shows how much their performance is driven by scientific news and regulatory decisions, rather than by general market trends.
Market capitalization of the company, segment and market as a whole
EYEN - Market capitalization of the company Eyenovia Inc.
Eyenovia's market capitalization reflects its focus on developing a drop-free technology for delivering ophthalmic medications via a micro-dose spray. Its volatile price is driven by news of clinical trials and regulatory decisions. This is a bet that its technology will become a new standard in ophthalmology.
EYEN - Share of the company's market capitalization Eyenovia Inc. within the market segment - Pharma eyes
Eyenovia is an ophthalmology company developing microdose eye drop technology. Its market share in the pharmaceutical sector is very small. Its market capitalization reflects the potential of its innovative drug delivery technology, which could become a new standard in eye disease treatment, and investors' confidence in its commercialization.
Market capitalization of the market segment - Pharma eyes
The graph below shows the market capitalization of the ophthalmic pharmaceutical sector. Eyenovia is developing a unique microdose technology for drug delivery to the eye, which promises to be more effective and convenient. Its market position reflects a bet that its innovative nebulizer could become a new standard in ophthalmology.
Market capitalization of all companies included in a broad market index - GURU.Markets
Eyenovia is developing a technology for delivering eye drops using microdoses, making treatment more precise and convenient. Its market capitalization is a bet on this innovation. The chart below shows the economic weight of companies improving existing treatment methods.
Book value capitalization of the company, segment and market as a whole
EYEN - Book value capitalization of the company Eyenovia Inc.
Eyenovia's foundation is its intellectual property in Optejet®, a precision ocular drug delivery technology, and the capital to commercialize its products. This chart tells the story of an ophthalmology company seeking to transform the treatment of eye diseases by investing in its unique nebulization technology.
EYEN - Share of the company's book capitalization Eyenovia Inc. within the market segment - Pharma eyes
Eyenovia develops devices for contactless delivery of eye drops. The chart shows its share of actual R&D assets. These are its laboratories where microdosing technology, its main material innovation, is being developed.
Market segment balance sheet capitalization - Pharma eyes
Eyenovia is an ophthalmology company developing a technology for microdose drug delivery to the eye. Their value lies in their technology and patents, not their manufacturing plants. A book value chart will show their R&D base, but it won't capture the potential of their innovative platform.
Book value of all companies included in the broad market index - GURU.Markets
Eyenovia's balance sheet includes laboratories and partner manufacturing facilities for developing their microdosing eye drop technology. The chart shows how the company built its capital to commercialize this innovative approach in ophthalmology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Eyenovia Inc.
Eyenovia develops innovative devices for delivering medications to the eye. Its value lies in its technology patents, not its manufacturing plants. The chart below is a classic biotech story. Market capitalization reflects not current assets, but the potential of its devices to transform ophthalmology and capture the market.
Market to book capitalization ratio in a market segment - Pharma eyes
Eyenovia develops innovative devices for delivering medications to the eye without the use of traditional eye drops (microdoses). Its value lies in this patented technology. The chart shows how its market capitalization, based on the potential of this innovation, significantly correlates with its current tangible assets.
Market to book capitalization ratio for the market as a whole
Eyenovia develops innovative devices for administering eye drops. Its value is determined by its patents and the potential of its technology to transform ophthalmology. This chart shows a typical biotech picture: the market valuation significantly exceeds the book value, reflecting investor expectations for approval and commercial success of the product.
Debts of the company, segment and market as a whole
EYEN - Company debts Eyenovia Inc.
Eyenovia is developing an innovative technology for delivering medications to the eye using microdroplets. This chart shows the company's financial position at the commercialization stage. Raising capital is necessary to obtain FDA approval and bring to market its unique device, which has the potential to transform ophthalmology.
Market segment debts - Pharma eyes
Eyenovia develops innovative devices for drug delivery to the eye, aiming to replace traditional eye drops. Commercializing new medical devices is a lengthy and expensive process. This chart shows the capital the company requires to overcome regulatory hurdles and bring its technology to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Eyenovia Inc.
Eyenovia is an ophthalmology company developing microdose eye drop technology. This chart shows its financial structure. For a company whose technology has not yet been widely adopted, debt is a significant risk. Success depends on regulatory approval and physician acceptance of the new technology.
Market segment debt to market segment book capitalization - Pharma eyes
Eyenovia is an ophthalmology pharmaceutical company developing microdosing technology for eye drops. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance the commercialization of its innovative drug delivery technology.
Debt to book value of all companies in the market
Eyenovia develops innovative devices for administering eye drops. This is a niche segment in ophthalmology. Commercializing a new medical device requires investment. This chart of total market debt helps understand how favorable the financial environment is for raising capital for such highly specialized medtech companies.
P/E of the company, segment and market as a whole
P/E - Eyenovia Inc.
Eyenovia develops innovative ophthalmic drugs using its proprietary microdose delivery technology (Optejet®), which enables more precise drug delivery with a smaller volume. This chart reflects investors' confidence in the superiority of this delivery technology.
P/E of the market segment - Pharma eyes
Eyenovia is an ophthalmology company developing medications for eye diseases using its proprietary Optejet microdosing technology, which enables more precise drug delivery. This chart shows the average valuation for the pharmaceutical sector, reflecting how investors value innovation in drug delivery methods.
P/E of the market as a whole
Eyenovia is a biopharmaceutical company developing a technology for delivering medications to the eye using microdroplets. Its valuation is a bet on the success of its unique technology. It is not tied to general economic cycles but depends on regulatory approval and partnerships with other pharmaceutical companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Eyenovia Inc.
Eyenovia is developing a technology for microdose eye drop delivery, improving treatment efficacy and convenience. This timeline reflects market expectations for the commercialization of its innovative ophthalmic devices. Future revenue is dependent on regulatory approval and acceptance by physicians and patients.
%20P%2FE%20Eyenovia%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Eyenovia-Inc.&v=1772641416722 "Chart of the company's future (projected) P/E Eyenovia Inc.")
Future (projected) P/E of the market segment - Pharma eyes
Eyenovia develops ophthalmic drugs using its microdosage delivery technology, which enables highly precise drug delivery to the eye. This chart shows general expectations for the pharmaceutical sector. EYEN's position relative to the average reflects whether investors believe their innovative delivery technology will become a new standard in ophthalmology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772641416764 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Eyenovia is an ophthalmic pharmaceutical company developing microdosing technology for drug delivery to the eye. Its Optejet device allows for more precise drug delivery with a smaller volume of liquid. This graph of overall market expectations provides a backdrop for evaluating innovative medical technologies that aim to improve existing treatment standards.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772641416780 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Eyenovia Inc.
Eyenovia develops technology for delivering ophthalmic medications in microdroplets, improving treatment efficacy and convenience. Its financial performance reflects the clinical trials and FDA approval phase. Future revenue depends on the successful commercialization of its innovative eye drops.
Profit of companies in the market segment - Pharma eyes
Eyenovia is an ophthalmology company developing microdose drug delivery technology for the eye, which could improve the efficacy and convenience of treatment. This chart represents the overall revenue of the ophthalmic pharmaceutical sector. It demonstrates the industry's overall success in combating eye diseases and commercializing innovative drug delivery methods.
Overall market profit
Eyenovia develops innovative devices for delivering medications to the eye that could replace traditional eye drops. The company's success depends on regulatory approval and the acceptance of its technology by doctors and patients. The overall economic situation, as shown in this chart, has less of an impact on its business than on companies dependent on consumer spending.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Eyenovia Inc.
Eyenovia is developing an innovative microdosing technology for ophthalmic drug delivery, which could improve the treatment of eye diseases. This graph reflects analysts' expectations for the commercial success of its Optejet platform, which is dependent on regulatory approval and acceptance by the medical community.
%20profit%20of%20the%20company%20Eyenovia%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Eyenovia-Inc.&v=1772641416832 "Graph of future (projected) profit of the company Eyenovia Inc.")
Future (predicted) profit of companies in the market segment - Pharma eyes
Eyenovia is developing an innovative technology for microdose drug delivery to the eye, which increases efficacy and reduces side effects. The company's future depends on regulatory approval of its products and technology. This graph reflects forecasts for the pharmaceutical sector, helping to assess Eyenovia's potential to change the standards of ophthalmological treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772641416879 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Eyenovia is a biopharmaceutical company developing microdosing technology for the treatment of eye diseases. Its success at this stage depends on regulatory approval and market acceptance. The general economic conditions reflected in this chart have minimal impact on its near-term prospects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772641416938 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Eyenovia Inc.
Eyenovia develops innovative devices for delivering medications to the eye using microdoses. This chart shows the market valuation of its technology, which promises to be more convenient and effective. The high multiple, despite its modest revenue, reflects hopes for regulatory approval and widespread adoption of its devices in ophthalmology.
P/S market segment - Pharma eyes
Eyenovia develops medications for eye diseases using its innovative microdosing technology (Optejet). Future revenue depends on the approval of its products. This chart for the ophthalmic pharmaceutical sector helps estimate the market premium the company is willing to pay for Eyenovia's technology, which could improve the delivery of eye drops.
P/S of the market as a whole
Eyenovia is an ophthalmology company developing microdosing technology for eye drops. Its devices deliver medication more precisely and with a smaller volume of liquid than traditional drops. This market revenue valuation chart helps understand how investors view this innovative drug delivery technology and its potential in ophthalmology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Eyenovia Inc.
Eyenovia develops innovative ophthalmic drugs using its proprietary microdosing technology, which enables more precise and effective drug delivery to the eye. This chart shows how the market estimates future sales of its products. It reflects expectations for regulatory approval and adoption in ophthalmological practice.
%20P%2FS%20Eyenovia%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Eyenovia-Inc.&v=1772641417191 "The graph of the company's future (projected) P/S Eyenovia Inc.")
Future (projected) P/S of the market segment - Pharma eyes
Eyenovia is developing an innovative Optejet technology for microdose eye drop delivery, which could improve efficacy and reduce side effects. The company's valuation is based on investors' belief in the potential of this technology and its pipeline of candidates for treating common eye conditions such as presbyopia and myopia.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772641417206 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Eyenovia, Inc. is developing a technology for microdose drug delivery to the eye, improving efficacy and comfort. This is an innovative approach in ophthalmology. In the context of the overall revenue projections shown in the chart, Eyenovia exemplifies technological advancement.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772641417209 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Eyenovia Inc.
Eyenovia is an ophthalmology company developing technology for drop-free drug delivery to the eye. While it is in the approval and commercialization stages, its revenue, if shown, is likely derived from licensing fees from partners or initial sales of its devices.
Sales of companies in the market segment - Pharma eyes
Eyenovia (EYEN) develops innovative ophthalmic drugs using its Optejet® microdose delivery technology. This method allows for precise drug delivery to the eye, reducing side effects. This chart shows revenue in the ophthalmic pharmaceutical sector. Eyenovia's technology has the potential to change the standard of care for many eye diseases.
Overall market sales
Eyenovia is developing innovative technologies for delivering medications into the eye using microdoses. Its potential success depends on regulatory approval and physician acceptance of its technology. This overall economic activity schedule impacts healthcare system funding and its willingness to implement new technologies that can improve patient compliance and treatment outcomes.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Eyenovia Inc.
Eyenovia is an ophthalmology company developing a technology for microdose drug delivery to the eye using a specialized nebulizer. Future revenue is dependent on the approval and commercialization of its products. This chart reflects analyst sales forecasts, which are a bet on the success of its innovative and more patient-friendly technology.
%20sales%20of%20the%20company%20Eyenovia%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Eyenovia-Inc.&v=1772641417281 "Schedule of future (projected) sales of the company Eyenovia Inc.")
Future (projected) sales of companies in the market segment - Pharma eyes
Eyenovia develops ophthalmic drugs using innovative microdroplet delivery technology. This forecast chart shows the potential future revenue from their pipeline of candidates after approval. This is an analyst's perspective on the commercial prospects of their technology, which could transform the treatment of eye diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772641417313 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Eyenovia develops innovative devices for ocular drug delivery that utilize microdoses for increased efficacy and comfort. Its technology has the potential to transform ophthalmology. This chart illustrates general healthcare trends, and Eyenovia's progress in obtaining regulatory approvals is a bet on a technological breakthrough in the treatment of ophthalmic diseases.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772641417324 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Eyenovia Inc.
Eyenovia is an ophthalmology company developing a technology for microdosed drug delivery to the eye, potentially replacing traditional eye drops. The company's profitability depends on regulatory approval and the acceptance of its technology by doctors and patients. The chart shows the financial trajectory of this innovative company, which aims to improve the treatment of eye diseases.
Market segment marginality - Pharma eyes
Eyenovia is an ophthalmic pharmaceutical company developing eye medications using its Optejet precision microdose delivery technology. This chart depicts its path to profitability. Success depends on regulatory approval of its products and physician and patient acceptance of its innovative drop delivery method.
Market marginality as a whole
Eyenovia, Inc. develops innovative ophthalmic medications using its dropper-delivery technology. The company's success depends on regulatory approval and physician acceptance of its products. This overall profitability chart reflects the state of the healthcare system. Financially stable clinics and insurers are more willing to implement new, more convenient treatment methods.
Employees in the company, segment and market as a whole
Number of employees in the company Eyenovia Inc.
Eyenovia develops innovative treatments for eye diseases using its microdosing technology, which enables more precise drug delivery. This chart shows the team advancing this cutting-edge platform and portfolio of ophthalmic drugs through clinical trials and regulatory approval.
Share of the company's employees Eyenovia Inc. within the market segment - Pharma eyes
Eyenovia develops innovative technologies for microdosing medications into the eye. This enables a focused team of scientists and engineers to create cutting-edge devices. This chart reflects its business model, where a small but highly skilled team is working on technology that has the potential to change standards in ophthalmology.
Number of employees in the market segment - Pharma eyes
Eyenovia, Inc. is developing innovative microdosing technology for the treatment of ophthalmic diseases. This chart, reflecting employment in ophthalmic pharmacology, demonstrates the intensity of research in this field. For Eyenovia, with its unique delivery device, the growing number of specialists indicates a large market where their technology can improve patient compliance.
Number of employees in the market as a whole
Eyenovia develops innovative technologies for ophthalmic drug delivery, such as microdosing pipettes. The adoption of new medical devices depends on the healthcare system's readiness to accept them. The growth in overall employment, reflected in this graph, supports healthcare funding, making it easier for doctors and patients to access more convenient and effective treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Eyenovia Inc. (EYEN)
Eyenovia (EYEN) is a biopharmaceutical company specializing in ophthalmology, specifically a new microdose eyedrop technology. This chart reflects their R&D valuation. The market doesn't value their staff, but rather their proprietary drug delivery technology and the potential of their drugs in the pipeline. This is classic biotech, where intellectual capital dominates labor.
%20of%20the%20company%20Eyenovia%20Inc.%20(EYEN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Eyenovia-Inc.-EYEN&v=1772641417630 "Chart of market capitalization per employee (in thousands of dollars) of the company Eyenovia Inc. (EYEN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Eyenovia develops medications for eye diseases using its microdosing technology. In pharmaceuticals, value is driven by innovation. This chart shows the market premium placed on its unique drug delivery technology, which can improve treatment and enhance patient comfort.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772641417631 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Eyenovia is an ophthalmology company developing technology for more precise drug delivery to the eye using microdroplets. This is a breakthrough in drug delivery. This chart for Eyenovia illustrates how even small but significant technological advances in medicine can create significant market value with the help of a small team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772641417682 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Eyenovia Inc. (EYEN)
Eyenovia is developing an innovative device for delivering eye drops (microdosing). The company is at the intersection of medical R&D and engineering. It is not yet profitable. This graph shows a negative value—the investment (loss) per employee the company is making in clinical trials and bringing its high-tech device to market.
%20Chart%20Eyenovia%20Inc.%20(EYEN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Eyenovia-Inc.-EYEN&v=1772641417704 "Company Profit Per Employee (in thousands of dollars) Chart Eyenovia Inc. (EYEN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Eyenovia is developing a technology for microdose drug delivery to the eye, increasing treatment effectiveness. In ophthalmology, where precision is paramount, the productivity of a small team of scientists and engineers is critical. This metric demonstrates the value each employee creates by bringing an innovative eye treatment to market.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772641417712 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Eyenovia is a biopharmaceutical company developing treatments for eye diseases (such as myopia) using its proprietary Optejet microdosing technology. This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be enormous if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772641417799 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Eyenovia Inc. (EYEN)
Eyenovia develops ophthalmic drugs using its innovative microdose delivery technology (Optejet). While commercializing its first products, its revenue per employee reflects the initial stage of market adoption. This graph tracks how this new technology is beginning to penetrate ophthalmology practice.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Eyenovia-Inc.-EYEN&v=1772641417847 "Sales chart per company employee Eyenovia Inc. (EYEN)")
Sales per employee in the market segment - Pharma eyes
Eyenovia (EYEN) is a biopharmaceutical company developing treatments for eye diseases using its precision drug delivery (microdose) technology. This chart shows the average revenue per employee in the segment. It helps assess how effectively Eyenovia is commercializing its innovative ophthalmology products.
Sales per employee for the market as a whole
Eyenovia (EYEN) is a biopharmaceutical company developing treatments for eye diseases using its patented microdosing technology (a spray instead of drops). The company is on the verge of commercialization. This metric, which is currently low, will be key after launch. It will indicate how effectively they can market their innovative product.
Short shares by company, segment and market as a whole
Shares shorted by company Eyenovia Inc. (EYEN)
Eyenovia (EYEN) is an ophthalmology company developing micro-dosing technology (spray) for eye medications. This chart shows short interest. The rising short interest may reflect investor doubts about the commercial success of its first approved product, Mydcombi, or concerns about the difficulty of obtaining approval for other drugs in the pipeline. (347)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Eyenovia-Inc.-EYEN&v=1772641417945 "Short Shares Chart for the Company Eyenovia Inc. (EYEN)")
Shares shorted by market segment - Pharma eyes
Eyenovia (EYEN) is a biopharmaceutical company developing microdosing technology for the treatment of eye diseases (such as myopia). The chart below shows the overall short position in the ophthalmology biotech sector. It reflects the extent to which investors are skeptical of new drug delivery methods or fearful of competition.
Shares shorted by the overall market
Eyenovia is a biotech company developing a new technology for delivering drugs to the eye. It's a pre-profit R&D story. This chart illustrates the overall market pessimism. When investors are afraid, they don't want to wait for FDA approvals. They sell off shares of cash-burning microcaps, fearing that EYEN won't be able to raise new capital on favorable terms.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Eyenovia Inc. (EYEN)
Eyenovia is developing a "micro-delivery" technology for drugs in the eye (Optejet), which could replace conventional eye drops. It's a risky biotech venture. This chart represents the FDA approval "pulse." Investor interest "overheats" to extremes before important regulatory decisions and "cools" on news of delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Eyenovia-Inc.-EYEN&v=1772641418156 "RSI 14 indicator chart for the company's stock Eyenovia Inc. (EYEN)")
RSI 14 Market Segment - Pharma eyes
Eyenovia is a biopharmaceutical company specializing in ophthalmology. It is known for its microdosing technology (Optejet), which enables more precise delivery of eye drops. This chart shows the overall sentiment in the ophthalmic pharmaceutical sector. It helps us understand whether EYEN's performance is a reaction to its technology or part of a broader trend.
RSI 14 for the overall market
Eyenovia (EYEN) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast EYEN (Eyenovia Inc.)
Eyenovia is an ophthalmology company that developed Optejet, an innovative micro-spray (MIST) that delivers medications to the eye (for example, for mydriasis) more precisely than eye drops. This chart shows the speculative average price target from analysts, based on their belief in FDA approval and commercialization of this technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EYEN-Eyenovia-Inc.&v=1772641418232 "A chart showing analyst consensus forecasts for the expected stock price. EYEN (Eyenovia Inc.)")
The difference between the consensus estimate and the actual stock price EYEN (Eyenovia Inc.)
Eyenovia is high-tech in ophthalmology. Their Optejet platform isn't eye drops, but a micro-spray designed to deliver medications more precisely and efficiently. This chart shows the analysts' forecast for the stock's upside and downside. It measures the gap between the price and forecast, reflecting their faith in this innovative R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EYEN-Eyenovia-Inc.&v=1772641418280 "A chart showing the difference between the consensus forecast and the actual stock price. EYEN (Eyenovia Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Eyenovia is a biotech company changing the way we deliver medicine. The company is developing a smart pipette (Optejet) that delivers microdoses of medications to the eye, increasing the effectiveness of glaucoma treatment. This chart shows analysts' overall expectations for the ophthalmic pharmaceutical sector. It reflects their confidence in new R&D technologies in ophthalmology.
Analysts' consensus forecast for the overall market share price
Eyenovia is a biotech company specializing in the treatment of eye diseases using its smart pipette (Optejet), which delivers microdoses of medications. This chart reflects the overall market "risk appetite." For Eyenovia, a clinical-stage company with an innovative delivery platform, overall market optimism (risk appetite) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Eyenovia Inc.
Eyenovia is a 21st-century eyedropper. Their signature feature isn't R&D for new drugs, but a new delivery method: their Optejet inkjet micro-doser (piezo printer), which (they claim) delivers a micro-dose of medication to the eye more precisely than older eye drops. This chart is a pure indicator of their R&D. It reflects their (slow) path to FDA approval and their (risky) platform bet.
AKIMA Market Segment Index - Pharma eyes
Eyenovia is a biopharmaceutical company that wants to free us from eye drops. They have developed a micro-spray (Optejet) that delivers medication to the eye more precisely and in smaller doses. This chart compares their composite index to the sector, showing how their innovative ocular delivery system outperforms the competition.
The AKIM Index for the overall market
Eyenovia is an ophthalmology company that developed Optejet microdosing technology for precise administration of ophthalmic medications. This chart, reflecting the market average, provides context. It helps assess how this innovative delivery platform, which improves patient comfort, compares to overall macroeconomic trends.
